Starbucks Is Earning More Per Customer Than It Has in Years. The Stock Is Priced as If That’s Just the Beginning.
In one breath The filed numbers show a business climbing out of a genuine hole: four straight quarters of comparable-sales...
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
In one breath The filed numbers show a business climbing out of a genuine hole: four straight quarters of comparable-sales...
In one breath Morgan Stanley's filed numbers show the best earnings per share in at least five years, a return...
The standing BullScope yardsticks for Bank Of America Corp /de/, computed from official filings and refreshed with each new edition.
Target built its modern identity on a simple promise: the cheap-chic discount store where a family could grab groceries, a...
The stock is trading near a decade high. The earnings multiple sits at its 81st percentile against its own ten-year...
The standing BullScope yardsticks for Apple, computed from official filings and refreshed with each new edition.
For most of the past five years, Boeing has been a company in the middle of a slow-motion correction. A...
In one breath The Q2 2026 10-Q filed July 24 shows American Express growing revenue at the fastest pace in...
Four years ago, inflation was the only story in America. The Consumer Price Index hit a number not seen since...
The standing BullScope yardsticks for Tonix Pharmaceuticals Holding, computed from official filings and refreshed with each new edition.
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer